دورية أكاديمية
Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers.
| العنوان: | Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. |
|---|---|
| المؤلفون: | Lindblad KE; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States.; Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute, New York, NY, United States.; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, NY, United States., Ruiz de Galarreta M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States.; Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute, New York, NY, United States., Lujambio A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States.; Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute, New York, NY, United States.; Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, NY, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2021 Apr 26; Vol. 12, pp. 642958. Date of Electronic Publication: 2021 Apr 26 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Tumor Escape*, Carcinoma, Hepatocellular/*immunology , Liver Neoplasms/*immunology, Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/pathology ; Humans ; Immunotherapy ; Liver Neoplasms/drug therapy ; Liver Neoplasms/genetics ; Liver Neoplasms/pathology |
| مستخلص: | Representing the fourth leading cause of cancer-related mortality worldwide, liver cancers constitute a major global health concern. Hepatocellular carcinoma (HCC), the most frequent type of liver cancer, is associated with dismal survival outcomes and has traditionally had few treatment options available. In fact, up until 2017, treatment options for advanced HCC were restricted to broad acting tyrosine kinase inhibitors, including Sorafenib, which has been the standard of care for over a decade. Since 2017, a multitude of mono- and combination immunotherapies that include pembrolizumab, nivolumab, ipilumumab, atezolizumab, and bevacizumab have been FDA-approved for the treatment of advanced HCC with unprecedented response rates ranging from 20 to 30% of patients. However, this also means that ~70% of patients do not respond to this treatment and currently very little is known regarding mechanisms of action of these immunotherapies as well as predictors of response to facilitate patient stratification. With the recent success of immunotherapies in HCC, there is a pressing need to understand mechanisms of tumor immune evasion and resistance to these immunotherapies in order to identify biomarkers of resistance or response. This will enable better patient stratification as well as the rational design of combination immunotherapies to restore sensitivity in resistant patients. The aim of this review is to summarize the current knowledge to date of tumor-intrinsic mechanisms of immune escape in liver cancer, specifically in the context of HCC. Competing Interests: Research grants from Pfizer and Genentech for unrelated projects AL. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Lindblad, Ruiz de Galarreta and Lujambio.) |
| References: | Lancet Oncol. 2019 Feb;20(2):282-296. (PMID: 30665869) Lancet Oncol. 2018 Jul;19(7):940-952. (PMID: 29875066) Front Immunol. 2019 Jul 16;10:1643. (PMID: 31379842) Biomed Pharmacother. 2016 May;80:289-297. (PMID: 27133068) Lancet. 2017 Jan 7;389(10064):56-66. (PMID: 27932229) Clin Cancer Res. 2008 Jul 1;14(13):4232-40. (PMID: 18594005) World J Gastroenterol. 2020 May 14;26(18):2126-2137. (PMID: 32476780) Liver Int. 2021 Jan;41(1):192-203. (PMID: 33098208) Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059) Cancer Discov. 2016 Feb;6(2):202-16. (PMID: 26645196) Sci Rep. 2020 Mar 19;10(1):5062. (PMID: 32193450) Nature. 2015 Jul 9;523(7559):231-5. (PMID: 25970248) Mucosal Immunol. 2008 Sep;1(5):372-81. (PMID: 19079201) Nature. 2018 Feb 22;554(7693):544-548. (PMID: 29443960) N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514) Hepatology. 2019 Jan;69(1):143-159. (PMID: 30070719) Cancer Cell. 2017 May 8;31(5):711-723.e4. (PMID: 28486109) Cell Mol Immunol. 2016 May;13(3):267-76. (PMID: 27063467) Nat Immunol. 2002 Nov;3(11):991-8. (PMID: 12407406) Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648) Front Oncol. 2019 Oct 15;9:1019. (PMID: 31681571) Oncotarget. 2019 Jun 18;10(40):4018-4025. (PMID: 31258846) J Clin Invest. 2019 Jul 15;129(8):3324-3338. (PMID: 31305264) Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526) Cancer Sci. 2018 Dec;109(12):3726-3736. (PMID: 30264546) Oncogenesis. 2019 Aug 13;8(8):43. (PMID: 31409774) Cancer Discov. 2019 Aug;9(8):1124-1141. (PMID: 31186238) Gastroenterology. 2019 May;156(6):1849-1861.e13. (PMID: 30711629) Cancer Discov. 2017 Nov;7(11):1320-1335. (PMID: 28790030) Cell. 2017 Jun 15;169(7):1327-1341.e23. (PMID: 28622513) Gut. 2019 Sep;68(9):1653-1666. (PMID: 30902885) Theranostics. 2020 May 17;10(14):6530-6543. (PMID: 32483468) Mol Med Rep. 2020 Apr;21(4):1849-1860. (PMID: 32319631) Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. (PMID: 30523282) Nat Immunol. 2018 Mar;19(3):222-232. (PMID: 29379119) N Engl J Med. 2018 Jul 05;379(1):54-63. (PMID: 29972759) J Immunother Cancer. 2018 Dec 10;6(1):145. (PMID: 30526680) Nature. 2018 Feb 22;554(7693):538-543. (PMID: 29443964) Cancer Res. 2009 Sep 15;69(18):7385-92. (PMID: 19723656) JCI Insight. 2019 Mar 21;4(6):. (PMID: 30895946) Aging (Albany NY). 2019 Aug 23;11(16):6422-6439. (PMID: 31442209) Hepatology. 2019 Jul;70(1):241-258. (PMID: 30854665) Cell. 2016 Sep 8;166(6):1485-1499.e15. (PMID: 27569912) Clin Cancer Res. 2019 May 15;25(10):3074-3083. (PMID: 30635339) Compr Physiol. 2013 Apr;3(2):567-98. (PMID: 23720323) J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550) J Hepatol. 2019 Jul;71(1):91-103. (PMID: 30930222) N Engl J Med. 2018 May 31;378(22):2093-2104. (PMID: 29658845) Gastroenterology. 2017 Sep;153(3):812-826. (PMID: 28624577) N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160) Annu Rev Immunol. 2018 Apr 26;36:247-277. (PMID: 29328785) Gastroenterology. 2017 Oct;153(4):1107-1119.e10. (PMID: 28648905) Cell. 2018 Feb 22;172(5):1022-1037.e14. (PMID: 29429633) J Hepatol. 2020 May;72(5):896-908. (PMID: 31887370) |
| معلومات مُعتمدة: | R37 CA230636 United States CA NCI NIH HHS; R01 CA251155 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: CTNNB1; hepatocellular carcinoma; immune escape; immune exclusion; immunotherapies |
| تواريخ الأحداث: | Date Created: 20210513 Date Completed: 20210927 Latest Revision: 20220216 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8107356 |
| DOI: | 10.3389/fimmu.2021.642958 |
| PMID: | 33981303 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!